Qiagen's (QGEN) "Equal Weight" Rating Reaffirmed at Morgan Stanley

Qiagen (NYSE:QGEN - Get Free Report)'s stock had its "equal weight" rating reissued by investment analysts at Morgan Stanley in a report issued on Monday, MarketBeat reports. They currently have a $48.00 price target on the stock, down from their previous price target of $50.00. Morgan Stanley's price target points to a potential upside of 7.19% from the company's current price.

QGEN has been the subject of a number of other reports. Hsbc Global Res upgraded Qiagen to a "hold" rating in a report on Thursday, October 17th. Jefferies Financial Group reiterated a "buy" rating and issued a $54.00 price target (up from $42.00) on shares of Qiagen in a report on Tuesday, December 10th. Finally, HSBC cut Qiagen from a "buy" rating to a "hold" rating and set a $49.00 price objective on the stock. in a research note on Thursday, October 17th. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $51.50.

Qiagen Trading Down 0.4 %

Qiagen stock traded down $0.19 during trading on Monday, reaching $44.78. The company had a trading volume of 850,197 shares, compared to its average volume of 662,866. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.89 and a current ratio of 2.17. The firm has a market capitalization of $10.22 billion, a price-to-earnings ratio of 114.82, a PEG ratio of 3.52 and a beta of 0.37. Qiagen has a 12-month low of $39.03 and a 12-month high of $47.44. The stock's 50 day moving average price is $43.81 and its two-hundred day moving average price is $43.84.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. GAMMA Investing LLC increased its holdings in shares of Qiagen by 170.1% in the 4th quarter. GAMMA Investing LLC now owns 1,518 shares of the company's stock valued at $68,000 after acquiring an additional 956 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Qiagen by 36.0% in the third quarter. JPMorgan Chase & Co. now owns 1,604,034 shares of the company's stock worth $73,096,000 after purchasing an additional 424,937 shares during the period. Tidal Investments LLC bought a new stake in Qiagen during the third quarter valued at $490,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Qiagen during the third quarter worth $53,000. Finally, Sanctuary Advisors LLC lifted its position in shares of Qiagen by 24.8% in the 3rd quarter. Sanctuary Advisors LLC now owns 19,506 shares of the company's stock worth $834,000 after buying an additional 3,878 shares during the last quarter. Institutional investors own 70.00% of the company's stock.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.